Warning letters increase as DSI rejigs operations

By Nick Taylor

- Last updated on GMT

Related tags: Government accountability office, Institutional review board

Warning letters increase as DSI rejigs operations
FDA warning letters to clinical trial investigators have increased by 50 per cent in 2009 as a consequence of improved processes at DSI, a spokesperson told Outsourcing-Pharma.

In a press statement issued in August the US Food and Drug Administration (FDA) detailed plans to clampdown on non-compliant investigators and enhance its debarment and disqualification measures.

A spokesperson for the FDA’s Center for Drug Evaluation and Research's (CDER's) Division of Scientific Investigations (DSI) told Outsourcing-Pharma how its operations had changed.

To increase the speed and efficiency of actions against misconduct DSI “staff members have been realigned so that the most serious cases of non-compliance are handled by reviewers dedicated to handling such cases​”.

Following this operational shift DSI “has improved its efficiency in issuing warning letters​”, according to the spokesperson, and this is supported by the data displayed below which plots the number issued in the past four years.

The increase in 2009 is part of a year-on-year rise in the number of warning letters issued to clinical investigators since 2006. Over this same period letters to institutional review boards (IRB) and clinical trial sponsors have fluctuated and remained low.

Following the US Government Accountability Office’s (GAO) investigation into Coast IRB there have been calls to reform the system in the US. The FDA intends to make IRBs register with the agency and is developing voluntary guidelines.

Data provided to Outsourcing-Pharma by DSI. Figures for 2009 were taken on August 21.

Related news

Show more

Related products

show more

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more